Genetic Function – Talk Bio

OpenAI launches ChatGPT Health as a dedicated, privacy-focused health assistant

2 weeks ago talkbio0Tagged Apple Health, b.well partnership, ChatGPT Health, DNA Integration, Health care facility, health data privacy, HealthBench, Healthcare AI, Medical Records, wellness apps * *

OpenAI; ChatGPT Health; healthcare AI; medical records integration; Apple Health; wellness apps; health data privacy; HealthBench; b.well partnership; AI in healthcare

Arrowhead’s RNAi Obesity Programs ARO-INHBE and ARO-ALK7 Advance with Encouraging Phase 1/2a Data

2 weeks ago talkbio0Tagged ARO-ALK7, ARO-INHBE, Arrowhead Pharmaceuticals, Obesity, Phase 1/2a, RNA Interference, tirzepatide, Weight Loss, Zepbound

Arrowhead Pharmaceuticals; ARO-INHBE; ARO-ALK7; RNAi; obesity; Phase 1/2a; tirzepatide; Zepbound; weight loss

Innovative Solutions for Difficult-to-Express Proteins: Cell-Free Systems and AI-Driven Advances

3 weeks ago talkbio0Tagged AI protein design, Alternative, Cell-free protein, Difficult-to-Express Proteins, Gene Expression, In Vitro [Publication Type]

cell-free protein expression; difficult-to-express proteins; AI protein design; in vitro expression; alternative proteins

SanegeneBio raises over $110M Series B after Lilly RNAi deal

2 months ago talkbio0Tagged clinical-stage assets, eli lilly, extrahepatic RNAi, Fund Raising, Lilly collaboration, liver-targeted RNAi, Metabolic Diseases, RNA, RNA Interference, SanegeneBio, Series B financing

SanegeneBio; Series B financing; $110 million; Eli Lilly; RNA interference; RNAi therapeutics; metabolic diseases; Lilly collaboration; clinical-stage assets; liver-targeted RNAi; extrahepatic RNAi; biotech fundraising 2025

Ansa Biotechnologies Appoints Geoff Hamilton as Chief Financial Officer and Chief Business Officer

2 months ago talkbio0Tagged Ansa, Biotechnology, CBO, CFO, Chief Business Officer, DNA Replication, executive appointment, Geoff Hamilton ; Chief Financial Officer, Leadership, Synthetic Biology

Ansa Biotechnologies; Geoff Hamilton; Chief Financial Officer; Chief Business Officer; CFO; CBO; executive appointment; synthetic biology; DNA synthesis; biotech leadership

GSK walks away from remaining IDEAYA programs, formally ending partnership

2 months ago talkbio0Tagged Collaboration termination, DNA Repair, drug development pipeline, Ideaya Biosciences, License Agreement, oncology partnership, Pol Theta, SmithKline Beecham, Synthetic Lethality, Werner helicase

GSK; IDEAYA Biosciences; synthetic lethality; collaboration termination; Werner helicase; Pol Theta; DNA damage repair; oncology partnership; license agreement; drug development pipeline

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig in Advanced Triple-Negative Breast Cancer

2 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, BREAST-01, disease control rate, Gene Expression, Myers Squibb, ORR, PD-L1, PD-L1xVEGF-A, Phase 2 trial, Progression-Free Survival, pumitamig, ROSETTA, SABCS, TNBC, Triple Negative Breast Neoplasms

BioNTech; Bristol Myers Squibb; pumitamig; BNT327; PD-L1xVEGF-A bispecific antibody; Phase 2 trial; triple-negative breast cancer; TNBC; confirmed ORR; disease control rate; progression-free survival; PD-L1 expression; ROSETTA BREAST-01; SABCS

Keytruda Breaks New Ground with FDA Approval for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

2 months ago talkbio0Tagged Adjuvant Therapy, Approved, Clinical Trials, Event-Free Survival, Gene Expression, KEYNOTE-689 trial, Keytruda, Neoadjuvant Therapy, PD-L1, pembrolizumab, perioperative, Squamous cell carcinoma of the head and neck, United States Food and Drug Administration

Keytruda; pembrolizumab; perioperative treatment; head and neck squamous cell carcinoma; HNSCC; FDA approval; KEYNOTE-689 trial; neoadjuvant therapy; adjuvant therapy; PD-L1 expression; event-free survival; clinical trial

Accelerating Breast Cancer Treatment Planning with Agentic AI: Recent Advances and Implementations (2025)

2 months ago talkbio0Tagged agentic AI, AI-guided, AWS HealthLake, Clinical Decision Support, DNA Integration, healthcare workflow, Malignant neoplasm of breast, Microsoft Teams, multi-agent systems, Neoplasms, Precision Medicine

agentic AI; breast cancer treatment; oncology; clinical decision support; multi-agent systems; healthcare workflow automation; personalized medicine; AWS HealthLake; Microsoft Teams integration; AI-guided treatment planning

Recent Advances in AI & Multi-Omics for Translational Research

2 months ago talkbio0Tagged agentic AI, AI-driven, Biological Markers, Cancer Research, Discover, DNA Integration, drug response, Machine Learning, Multiomics, Precision Medicine, Prediction, Stratification, Study models, Translational Research, Biomedical

AI-driven multi-omics integration; translational research; precision medicine; biomarker discovery; patient stratification; machine learning; foundation models; agentic AI; cancer research; drug response prediction